DK1073723T3 - STE20-relaterede proteinkinaser - Google Patents

STE20-relaterede proteinkinaser

Info

Publication number
DK1073723T3
DK1073723T3 DK99918539T DK99918539T DK1073723T3 DK 1073723 T3 DK1073723 T3 DK 1073723T3 DK 99918539 T DK99918539 T DK 99918539T DK 99918539 T DK99918539 T DK 99918539T DK 1073723 T3 DK1073723 T3 DK 1073723T3
Authority
DK
Denmark
Prior art keywords
ste20
protein kinases
nucleic acid
acid molecules
molecules encoding
Prior art date
Application number
DK99918539T
Other languages
Danish (da)
English (en)
Inventor
Gregory Plowman
Ricardo Martinez
David Whyte
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc filed Critical Sugen Inc
Application granted granted Critical
Publication of DK1073723T3 publication Critical patent/DK1073723T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK99918539T 1998-04-14 1999-04-13 STE20-relaterede proteinkinaser DK1073723T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8178498P 1998-04-14 1998-04-14

Publications (1)

Publication Number Publication Date
DK1073723T3 true DK1073723T3 (da) 2006-01-02

Family

ID=22166386

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99918539T DK1073723T3 (da) 1998-04-14 1999-04-13 STE20-relaterede proteinkinaser

Country Status (10)

Country Link
US (5) US6680170B2 (fr)
EP (1) EP1073723B1 (fr)
JP (1) JP2002522009A (fr)
AT (1) ATE302269T1 (fr)
AU (1) AU3642499A (fr)
CA (1) CA2369172A1 (fr)
DE (1) DE69926742T2 (fr)
DK (1) DK1073723T3 (fr)
ES (1) ES2248997T3 (fr)
WO (1) WO1999053036A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078182B1 (en) * 1998-04-14 2006-07-18 Board Of Regents, The University Of Texas System TAO protein kinase polypeptides and methods of use therefor
US6013500A (en) * 1998-05-21 2000-01-11 The Trustees Of Columbia University In The City Of New York PAK4, a novel gene encoding a serine/threonine kinase
JP2002525058A (ja) * 1998-09-10 2002-08-13 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー プロテインキナーゼｋｉａａ０５５１の薬剤としての使用
WO2000049139A2 (fr) * 1999-02-19 2000-08-24 Mcmaster University Proteine kinase activee par la caspase
WO2000060062A2 (fr) * 1999-04-01 2000-10-12 Astrazeneca Uk Limited Serine/threonine proteine kinase de transduction de signaux d'origine humaine
US6558903B1 (en) * 1999-06-30 2003-05-06 Millennium Pharmaceuticals, Inc. Kinases and uses thereof
WO2001009316A1 (fr) * 1999-07-29 2001-02-08 Helix Research Institute Nouveaux genes codant la proteine kinase / proteine phosphatase
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
US6861239B1 (en) 1999-09-20 2005-03-01 New York University Genes and polynucleotides associated with ultraviolet radiation-mediated skin damage and uses thereof
AU1855001A (en) 1999-11-15 2001-05-30 Pharmacia & Upjohn S.P.A. A new member of the pak protein family, nucleic acids and methods related to thesame
EP1254214A2 (fr) * 2000-01-25 2002-11-06 Sugen, Inc. Nouvelles proteines kinases humaines et enzymes semblables aux proteines kinases
WO2002024947A2 (fr) * 2000-09-20 2002-03-28 Kinetek Pharmaceuticals, Inc. Proteines kinases associees au cancer et leurs applications
EP1349935A2 (fr) * 2001-01-12 2003-10-08 Incyte Genomics, Inc. Molecules pour la detection et le traitement de maladies
US7265214B2 (en) * 2001-10-19 2007-09-04 Rigel Pharmaceuticals, Inc. Germinal center kinase proteins, compositions and methods of use
EP1501923A4 (fr) 2001-12-28 2007-02-07 Univ Columbia Compositions et procedes associes a pak5
EP1539956B1 (fr) * 2002-07-05 2011-01-26 Sugen, Inc. Gef-h1b: biomarqueurs, complexes, essais et utilisations therapeutiques correspondantes
GB0220770D0 (en) * 2002-09-06 2002-10-16 Ares Trading Sa Proteins
US20050054017A1 (en) 2002-11-27 2005-03-10 Sugen, Inc. Phosphospecific PAK antibodies and diagnostic kits
WO2004056982A2 (fr) * 2002-12-23 2004-07-08 Devgen Nv Sequences de kinases
GB2396615A (en) * 2002-12-23 2004-06-30 Devgen Nv Kinase sequences useful for developing compounds for the prevention and/or treatment of metabolic diseases
US20040242461A1 (en) * 2003-04-08 2004-12-02 Schneider Michael D. Modulators of telomere stability
CA2535261C (fr) * 2003-08-13 2015-11-24 Chiron Corporation Reactifs peptidiques specifiques du prion
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
WO2005030259A2 (fr) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Conjugues lipophiles d'acides nucleiques
WO2005111234A2 (fr) * 2004-05-12 2005-11-24 Sugen, Inc. Procedes d'utilisation de phosphorylation de substrat de kinase zc1 et zc3 pour l'etablissement de biomarqueurs
WO2006076683A2 (fr) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolement et detection de prions pathogenes
EP1848831A4 (fr) * 2005-01-13 2008-11-05 Novartis Vaccines & Diagnostic Dosages elisa utilisant des reactifs peptides specifiques du prion
US20090099343A1 (en) * 2005-01-13 2009-04-16 David Peretz Isolation of pathogenic prions
US7834144B2 (en) * 2005-09-09 2010-11-16 Novartis Ag Prion-specific peptoid reagents
BRPI0910550A2 (pt) * 2008-04-30 2015-09-29 Novartis Ag ensaio para confôrmeros patogênicos
KR101219395B1 (ko) * 2010-07-15 2013-01-11 전자부품연구원 리튬이차전지용 양극재료 및 그의 제조방법
CN107267649B (zh) * 2017-08-08 2018-08-14 常州市第二人民医院 Stradb在哮喘早期诊断中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343940A (en) 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
EP0031237B1 (fr) 1979-12-19 1984-10-17 National Research Development Corporation Dérivés de la quinazoline, procédés pour leur préparation, compositions les contenant et leur utilisation comme agents anticancéreux
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
DE3611194A1 (de) 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3920029C2 (de) 1988-06-30 1999-05-20 Clariant Finance Bvi Ltd Farbstoffe zum Färben von Kunststoffen
CA2078214C (fr) 1990-04-02 1995-03-28 Robert Lee Dow Inhibiteur de tyrosine kinase a base d'acide phenylmethanephosphonique
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
ES2108120T3 (es) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
US6194439B1 (en) 1991-05-29 2001-02-27 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9205320D0 (en) 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
HUT71553A (en) 1992-08-06 1995-12-28 Warner Lambert Co 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5366889A (en) * 1992-11-30 1994-11-22 The General Hospital Corporation DNA encoding a protein-coupled receptor kinase
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
WO1997042212A1 (fr) * 1996-05-07 1997-11-13 The General Hospital Corporation Sok-1 et techniques d'utilisation
WO1998015635A2 (fr) 1996-10-04 1998-04-16 Connaught Laboratories Limited Traitement de cancer au moyen d'un poxvirus contenant une sequence nucleotidique codant pour une cytokine
WO1999002699A1 (fr) * 1997-07-08 1999-01-21 Cadus Pharmaceutical Corporation Molecules de proteine kinase kds et utilisations de ces molecules
AU8778698A (en) * 1997-08-11 1999-03-01 Ontogeny, Inc. Serine/threonine kinase, and uses related thereto
GB9719920D0 (en) * 1997-09-19 1997-11-19 Zeneca Ltd Human Ste20-Like Stress Activated Serine/Threonine Kinase
GB9726851D0 (en) * 1997-12-19 1998-02-18 Zeneca Ltd Human signal transduction serine/threonine kinase
US6013500A (en) * 1998-05-21 2000-01-11 The Trustees Of Columbia University In The City Of New York PAK4, a novel gene encoding a serine/threonine kinase

Also Published As

Publication number Publication date
ATE302269T1 (de) 2005-09-15
JP2002522009A (ja) 2002-07-23
EP1073723A2 (fr) 2001-02-07
WO1999053036A3 (fr) 2000-05-11
WO1999053036A9 (fr) 2000-02-17
US20050142625A1 (en) 2005-06-30
US20030050230A1 (en) 2003-03-13
DE69926742D1 (de) 2005-09-22
EP1073723B1 (fr) 2005-08-17
CA2369172A1 (fr) 1999-10-21
WO1999053036A2 (fr) 1999-10-21
DE69926742T2 (de) 2006-06-14
US20040224323A1 (en) 2004-11-11
AU3642499A (en) 1999-11-01
US6656716B1 (en) 2003-12-02
ES2248997T3 (es) 2006-03-16
US20070072261A1 (en) 2007-03-29
US6680170B2 (en) 2004-01-20

Similar Documents

Publication Publication Date Title
ATE302269T1 (de) Ste20-verwandte proteinkinasen
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
EA200500053A1 (ru) Способы получения замещённых пиримидинов и производных пиримидинов в качестве ингибиторов протеинкиназ
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA200600591A1 (ru) МОДУЛИРОВАНИЕ ЭКСПРЕССИИ eIF4E
WO2000073469A3 (fr) Proteines kinases
TW200505480A (en) High concentration antibody and protein formulations
NO20022359D0 (no) Inhibering av genekspresjon med dsRNA
EP1546179A4 (fr) Modulation antisens de l'expression de kinase de type polo
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
ATE289200T1 (de) Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
EP1430072A4 (fr) Modulation antisens de l'expression de la proteine de transfert de l'ester de cholesteryle
TW200517178A (en) Hollow fiber membrane for blood purification and blood purification apparatus including the same
WO2004009024A3 (fr) Modulation de l'expression de la proteine kinase c-iota
WO2003105755A3 (fr) Modulation antisens de l'expression du facteur de croissance endotheliale vasculaire c (vegf-c)
WO1998011234A3 (fr) Proteines kinases humaines
SG158739A1 (en) Aggrecanase molecules
WO2001031051A3 (fr) Modulation par antisens de l'expression de la proteine kinase c-theta
WO2002062818A3 (fr) Modulation antisens de l'expression de la caseine kinase 2-alpha
WO2004047727A3 (fr) Compositions et procedes pour diagnostiquer et traiter des troubles de l'humeur
WO1999066051A3 (fr) Kinases en rapport avec nek et avec bub1